Journal Article

Rationale and design of a large trial of perioperative ketamine for prevention of chronic post-surgical pain

Myles, Paul S., Holmes, Alex, Chan, Matthew, Evered, Lisbeth, Peyton, Philip J., Braat, Sabine, De Silva, Anurika, Story, David, Leslie, Kate, Hogg, Malcolm, Schug, Stephan, Sidiropoulos, Sofia

2024

Overview

Background Chronic post-surgical pain (CPSP) is recognised as one of the most common and debilitating complications of major surgery. Progression from acute to chronic pain after surgery involves sensitisation of central nervous system pathways with the N-methyl-D-aspartate (NMDA) receptor having a central role. Ketamine is a potent, non-selective NMDA antagonist commonly used for management of acute postoperative pain. Inconsistent but largely supportive evidence from small trials of a preventative effect of perioperative ketamine on CPSP risk suggests that a confirmative large trial is needed. Methods The ROCKet ( R eduction O f C hronic Post-surgical Pain with Ket amine) Trial is a multicentre, double-blind, placebo-controlled, individually randomised superiority trial conducted in 36 hospitals across Australia, New Zealand, and Hong Kong. The trial aims to recruit 4884 patients undergoing abdominal, thoracic, or major orthopaedic surgery. Eligible participants are randomised equally to perioperative intravenous ketamine or placebo for up to 72 h. Incidence of pain in the area of the index surgery is measured by structured telephone interview at 3 months (primary trial endpoint) and 12 months. Pain severity, nature, and associated psychological and quality of life indices are measured using the modified Brief Pain Inventory short form, Neuropathic Pain Questionnaire, Kessler K-10 Psychological Distress Scale, Pain Catastrophising Scale, EQ-5D-3L, and measures of healthcare utilisation and costs. The trial is being conducted by the Department of Critical Care, University of Melbourne, and the Australian and New Zealand College of Anaesthetists Clinical Trials Network. The trial is funded by the Australian National Health and Medical Research Council. Discussion The ROCKet trial will clarify the effectiveness of ketamine in primary prevention of CPSP. In addition, it will provide high-quality, prospective data on the epidemiology of CPSP which will better inform further research into prevention and management of CPSP. Trial registration Australian New Zealand Clinical Trials Registry (ACTRN12617001619336) on the date of 12/11/2017.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Abdomen / Analgesics - adverse effects / Analgesics - therapeutic use / Anesthesia / Aspartate / Australia / Biomedicine / Body mass index / Care and treatment / Chronic pain / Chronic Pain - drug therapy / Chronic Pain - prevention & control / Clinical trials / Data collection / Double-Blind Method / Epidemiology / Equivalence Trials as Topic / Grants / Health Sciences / Hong Kong / Hospitals / Humans / Intervention / Ketamine / Ketamine - administration & dosage / Ketamine - adverse effects / Ketamine - therapeutic use / Mastectomy / Medical care, Cost of / Medical research / Medicine / Medicine & Public Health / Medicine, Experimental / Methodology / Methyl aspartate / Multicenter Studies as Topic / Narcotics / New Zealand / Nitrous oxide / Ostomy / Pain / Pain Measurement / Pain, Postoperative / Pain, Postoperative - diagnosis / Pain, Postoperative - drug therapy / Pain, Postoperative - etiology / Pain, Postoperative - prevention & control / Perioperative Care - methods / Postoperative period / Prevention / Quality of Life / Questionnaires / Randomized Controlled Trials as Topic / Registration / Spinal cord / Statistics for Life Sciences / Stress (Psychology) / Thoracic surgery / Time Factors / Treatment Outcome